NEA leads $53 mln round for Senti Biosciences
South San Francisco-based Senti Biosciences, a synthetic biology company, has closed $53 million in funding. New Enterprise Associates led the round with participation from 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital and LifeForce Capital.
27 February 2018•1 min read
